secwatch.observer — SEC 8-K summary
======================================

Issuer:     Artiva Biotherapeutics, Inc. (ARTV)
CIK:        0001817241
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0000950170-25-104028
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artiva reports Q2 net loss $21.3M; cash runway into Q2 2027; autoimmune trial progress
--------------------------------------------------------------------------------

- Net loss of $21.3M for Q2 2025 vs $17.8M in Q2 2024; R&D expenses $17.9M (up from $12.3M).
- Cash, cash equivalents, and investments $142.4M as of June 30, 2025; funding into Q2 2027.
- First patient treated in global Phase 2a basket trial of AlloNK + rituximab in refractory RA, Sjögren's, myositis, and scleroderma.
- Over a dozen patients treated across autoimmune trials; initial safety/translational data by year-end 2025.
- Lead indication for AlloNK to be disclosed by year-end 2025; initial clinical response data in 1H2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817241/000095017025104028/0000950170-25-104028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817241/000095017025104028/artv-20250806.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-104028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer